Curcumin is a major component of the plant Curcuma longa L. It is traditionally used as a spice and coloring in foods and is an important ingredient in curry.
Curcuminoids have
anti-oxidant and anti-inflammatory properties and gained increasing attention as potential neuroprotective and
cancer preventive compounds. In the present study, we report that
curcumin is a potent tight-binding inhibitor of human
carbonyl reductase 1 (CBR1, Ki=223 nM).
Curcumin acts as a non-competitive inhibitor with respect to the substrate 2,3-hexandione as revealed by plotting IC50-values against various substrate concentrations and most likely as a competitive inhibitor with respect to
NADPH. Molecular modeling supports the finding that
curcumin occupies the cofactor binding site of CBR1. Interestingly, CBR1 is one of the most effective human
reductases in converting the
anthracycline anti-
tumor drug daunorubicin to
daunorubicinol. The secondary alcohol metabolite
daunorubicinol has significantly reduced anti-
tumor activity and shows increased
cardiotoxicity, thereby limiting the clinical use of
daunorubicin. Thus, inhibition of CBR1 may increase the efficacy of
daunorubicin in
cancer tissue and simultaneously decrease its
cardiotoxicity. Western-blots demonstrated basal expression of CBR1 in several cell lines. Significantly less
daunorubicin reduction was detected after incubating A549 cell lysates with increasing concentrations of
curcumin (up to 60% less with 50 μM
curcumin), suggesting a beneficial effect in the co-treatment of
anthracycline anti-
tumor drugs together with
curcumin.